![conference banner](/images/conference-banner.jpeg)
Abstract
High molecular weight kininogen (HK) is a plasma protein that is cleaved by plasma kallikrein in the clinical settings of sepsis and chronic inflammatory diseases such as rheumatoid arthritis and Crohns disease. This proteolytic event results in a nonapeptide, bradykinin (BK), and a kinin-free derivative of HK, namely HKa. BK promotes angiogenesis by upregulation of bFGF through the B1 receptor or by stimulation of VEGF formation via the B2 receptor. Kininogen- deficient rats show diminished angiogenesis when neovascularization is stimulated. The formation of HKa results in exposure of domain 5 (D5). HKa or D5 inhibit endothelial cell migration and proliferation, both of which are needed for angiogenesis. In the chicken chorioallantoic membrane assay when neovascularization is stimulated by bFGF or VEGF, HKa or D5 inhibit angiogenesis. Monoclonal antibody C11C1, which prevents binding of HK to endothelial cells, also limits its conversion to BK thus downregulating angiogenesis. In vivo, mAb C11C1 inhibits tumor angiogenesis in mice as well as in experimental inflammatory arthritis and inflammatory bowel disease in Lewis rats. In vitro HKa or D5 inhibits endothelial cell adhesion to vitronectin and fibrinogen, resulting in anokis and apoptosis. The HKa receptor, uPAR, forms a signaling complex containing the integrin αvβ3 or α5β1, caveolin, Src kinase Yes, focal adhesion kinase and paxcillin. HKa physically disrupts the complex by interfering with the binding of vitronectin to uPAR. Both mAb C11C1 and D5 have potential applications for controlling unwanted angiogenesis in inflammation and cancer.
Keywords: Factor XII, prekallikrein, kininogen, urokinase plasminogen activator, bradykinin, kininostatin, vitronectin
Current Pharmaceutical Design
Title: Regulation of Angiogenesis by the Kallikrein-Kinin System
Volume: 12 Issue: 21
Author(s): Robert W. Colman
Affiliation:
Keywords: Factor XII, prekallikrein, kininogen, urokinase plasminogen activator, bradykinin, kininostatin, vitronectin
Abstract: High molecular weight kininogen (HK) is a plasma protein that is cleaved by plasma kallikrein in the clinical settings of sepsis and chronic inflammatory diseases such as rheumatoid arthritis and Crohns disease. This proteolytic event results in a nonapeptide, bradykinin (BK), and a kinin-free derivative of HK, namely HKa. BK promotes angiogenesis by upregulation of bFGF through the B1 receptor or by stimulation of VEGF formation via the B2 receptor. Kininogen- deficient rats show diminished angiogenesis when neovascularization is stimulated. The formation of HKa results in exposure of domain 5 (D5). HKa or D5 inhibit endothelial cell migration and proliferation, both of which are needed for angiogenesis. In the chicken chorioallantoic membrane assay when neovascularization is stimulated by bFGF or VEGF, HKa or D5 inhibit angiogenesis. Monoclonal antibody C11C1, which prevents binding of HK to endothelial cells, also limits its conversion to BK thus downregulating angiogenesis. In vivo, mAb C11C1 inhibits tumor angiogenesis in mice as well as in experimental inflammatory arthritis and inflammatory bowel disease in Lewis rats. In vitro HKa or D5 inhibits endothelial cell adhesion to vitronectin and fibrinogen, resulting in anokis and apoptosis. The HKa receptor, uPAR, forms a signaling complex containing the integrin αvβ3 or α5β1, caveolin, Src kinase Yes, focal adhesion kinase and paxcillin. HKa physically disrupts the complex by interfering with the binding of vitronectin to uPAR. Both mAb C11C1 and D5 have potential applications for controlling unwanted angiogenesis in inflammation and cancer.
Export Options
About this article
Cite this article as:
Colman W. Robert, Regulation of Angiogenesis by the Kallikrein-Kinin System, Current Pharmaceutical Design 2006; 12 (21) . https://dx.doi.org/10.2174/138161206777698710
DOI https://dx.doi.org/10.2174/138161206777698710 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design EPA and DHA Differentially Affect In Vitro Inflammatory Cytokine Release by Peripheral Blood Mononuclear Cells from Alzheimer’s Patients
Current Alzheimer Research Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews Impact of Bioactive Compounds in the Management of Various Inflammatory Diseases
Current Pharmaceutical Design Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Pre-Eclampsia: Immunological Aspects - A Role of Adhesion Molecules, Cytokines, Dendritic Cells, MHC Antigens and Auto-Antibodies
Current Women`s Health Reviews Synthesis, Characterization, Antitubercular and Anti-Inflammatory Activity of New Pyrazolo[3,4-d]Pyrimidines
Combinatorial Chemistry & High Throughput Screening Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research Incidence and Prevention of Thromboembolic Events in One Stage Bilateral Total Hip Arthroplasty: A Systematic Review
Current Vascular Pharmacology A Review of the English and Russian Language Literature on the Osteoarticular Manifestations of Brucellosis Infection
Current Rheumatology Reviews S100A9 Exacerbates the Aβ1-42-mediated Innate Immunity in Human THP-1 Monocytes
CNS & Neurological Disorders - Drug Targets Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Cardiovascular Disease in Antiphospholipid Syndrome
Current Vascular Pharmacology Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets CENPA a Genomic Marker for Centromere Activity and Human Diseases
Current Genomics Anti-Nociceptive and Anti-Inflammatory Effects of Stem Bark Extract of <i>Ficus Capensis</i> Thunb (Moraceae) by Bioactivity Fractionation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prostaglandin E2 Binding Peptide: a Potential Modulatory Agent which Acts Through Suppressing NF-kappaB Signaling in RA
Protein & Peptide Letters Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets